{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:49:40Z","timestamp":1779241780193,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1056,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Accumetrics"},{"name":"AstraZeneca"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Intekrin Therapeutics"},{"name":"Merck"},{"name":"Takeda"},{"name":"AstraZeneca"},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beckman Coulter Inc."},{"name":"Eli Lilly"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Integrated Therapeutics Group"},{"DOI":"10.13039\/100004334","name":"Merck & Co. Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche Diagnostics Corp."},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.jacc.2010.06.028","type":"journal-article","created":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T07:27:25Z","timestamp":1286954845000},"page":"1376-1385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prior Aspirin Use and Outcomes in Acute Coronary Syndromes"],"prefix":"10.1016","volume":"56","author":[{"given":"Jonathan D.","family":"Rich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2010.06.028_bib1","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.06.028_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.06.028_bib4","first-page":"81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy: I","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2010.06.028_bib5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM199201303260506","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes (2)","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2010.06.028_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0002-9149(99)00049-1","article-title":"Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes","volume":"83","author":"Alexander","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0167-5273(01)00495-8","article-title":"Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox","volume":"80","author":"Lancaster","year":"2001","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1067\/mhj.2001.113994","article-title":"Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin","volume":"141","author":"Santopinto","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.06.028_bib12","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.CIR.89.4.1545","article-title":"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction","volume":"89","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1053\/euhj.2000.2498","article-title":"Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction","volume":"21","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.06.028_bib16","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.99.21.2720","article-title":"Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial","volume":"99","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib17","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.06.028_bib20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib21","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/01.CIR.98.25.2805","article-title":"TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial","volume":"98","author":"Cannon","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/0735-1097(94)90163-5","article-title":"Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial","volume":"24","author":"Cannon","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.95.2.351","article-title":"TNK-tissue plasminogen activator in acute myocardial infarction","volume":"95","author":"Cannon","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","article-title":"Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib25","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0735-1097(03)00123-2","article-title":"Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) phase II angiographic trial","volume":"41","author":"Giugliano","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ahj.2005.01.007","article-title":"Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial","volume":"150","author":"Ohman","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.06.028_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib29","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.06.028_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.06.028_bib32","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/01.CIR.102.17.2031","article-title":"TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy","volume":"102","author":"Morrow","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0002-9149(02)02769-8","article-title":"Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE])","volume":"90","author":"Spencer","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib34","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2005.06.049","article-title":"Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction","volume":"46","author":"Portnay","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijcard.2005.07.081","article-title":"Prior clopidogrel use and outcome of acute coronary syndrome","volume":"111","author":"Soiza","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0002-9149(97)01006-0","article-title":"Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina","volume":"81","author":"Borzak","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib37","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archinte.1995.00430130064007","article-title":"Does aspirin consumption affect the presentation or severity of acute myocardial infarction?","volume":"155","author":"Col","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2010.06.028_bib38","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/01.CIR.92.7.1743","article-title":"Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes","volume":"92","author":"Garcia-Dorado","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib39","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0002-9149(00)01071-7","article-title":"Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction","volume":"86","author":"Dauerman","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib40","first-page":"e25","article-title":"Heart Disease and Stroke Statistics\u20142008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"117","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.028_bib41","doi-asserted-by":"crossref","first-page":"11N","DOI":"10.1016\/j.amjcard.2006.09.009","article-title":"Aspirin resistance or variable response or both?","volume":"98","author":"Cheng","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.028_bib42","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance","volume":"113","author":"Frelinger","year":"2006","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710034522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710034522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:41:35Z","timestamp":1760013695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109710034522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":42,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0735109710034522"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.06.028","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prior Aspirin Use and Outcomes in Acute Coronary Syndromes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}